300049.SHE Inner Mongolia Furui Med Sci
- Market cap
- CNY 10.3B
- P/E
- 54.3x
- P/B
- 5.00x
- ROE
- 9.0%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300049.SHE undervalued?
Graham numberThe Graham number of Inner Mongolia Furui Med Sci cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inner Mongolia Furui Med Sci fundamental analysis
No fundamental analysis for Inner Mongolia Furui Med Sci yet.
Inner Mongolia Furui Med Sci stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liver disease; and FibroView data management software. It provides digital health m…
Full company profileInner Mongolia Furui Med Sci financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inner Mongolia Furui Med Sci annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 827M | 823M | 867M | 832M | 808M | 898M | 1.01B | 1.15B | 1.35B | 1.59B | 1.52B |
| Gross Profit | 596M | 606M | 606M | 593M | 581M | 659M | 741M | 862M | 998M | 1.09B | 1.15B |
| Operating Income | 186M | 139M | 123M | 127M | 120M | 189M | 193M | 253M | 278M | 400M | 372M |
| EBITDA | 211M | 196M | 165M | 193M | 210M | 221M | 236M | 308M | 359M | 505M | 391M |
| Net Income | 121M | 61.1M | 35.4M | 43.4M | 61.9M | 95.5M | 97.9M | 102M | 113M | 154M | 178M |
| EPS | 0.46 | 0.23 | 0.13 | 0.17 | 0.24 | 0.37 | 0.37 | 0.39 | 0.43 | 0.59 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 2.41B | 2.51B | 2.14B | 2.25B | 2.29B | 2.52B | 2.52B | 2.65B | 3.06B | 3.44B | 3.47B |
| Total Liabilities | 581M | 594M | 622M | 699M | 675M | 719M | 697M | 800M | 931M | 652M | 938M |
| Shareholders' Equity | 1.46B | 1.50B | 1.33B | 1.32B | 1.35B | 1.52B | 1.55B | 1.55B | 1.75B | 1.98B | 1.99B |
| Cash & Short-term Investments | 868M | 788M | 299M | 435M | 516M | 619M | 615M | 604M | 724M | 733M | 635M |
| Total Debt | 70.2M | 85.0M | 78.5M | 109M | 115M | 94.1M | 43.0M | 44.9M | 55.2M | 137M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 149M | 132M | 78.3M | 256M | 200M | 223M | 189M | 305M | 221M | 354M | - |
| Capital Expenditure | 214M | 39.6M | 94.0M | 66.3M | 110M | 79.6M | 90.8M | 189M | 219M | 189M | 155M |
| Free Cash Flow | -64.7M | 86.5M | -15.6M | 190M | 90.4M | 129M | 98.7M | 116M | 2.44M | 165M | 207M |
| Ratios | |||||||||||
| ROE | 8.3% | 4.1% | 2.7% | 3.3% | 4.6% | 6.3% | 6.3% | 6.6% | 6.5% | 7.8% | 9.0% |
| ROA | 5.0% | 2.4% | 1.7% | 1.9% | 2.7% | 3.8% | 3.9% | 3.8% | 3.7% | 4.5% | 5.1% |
| Net Profit Margin | 14.6% | 7.4% | 4.1% | 5.2% | 7.7% | 10.6% | 9.7% | 8.8% | 8.4% | 9.7% | 11.7% |
| Debt to Equity | 0.05x | 0.06x | 0.06x | 0.08x | 0.09x | 0.06x | 0.03x | 0.03x | 0.03x | 0.07x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inner Mongolia Furui Med Sci dividends
- Dividend yield
- 0.02%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 1.5%
- Ex-dividend date
- Jul 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.29M | 0.01 | 1.5% |
| 2024 | CNY 2.20M | 0.01 | 1.9% |
| 2023 | CNY 53.4M | 0.20 | 52.6% |
| 2022 | CNY 71.4M | 0.27 | 73.0% |
| 2021 | CNY 1.95M | 0.01 | 2.0% |
| 2020 | CNY 3.76M | 0.01 | 6.1% |
| 2019 | CNY 2.97M | 0.01 | 6.8% |
| 2018 | CNY 31.1M | 0.11 | 87.9% |
| 2017 | CNY 32.3M | 0.12 | 52.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 6, 2015.
Who owns Inner Mongolia Furui Med Sci
- Insiders 24.57%
- Institutions 10.92%
- Public & others 64.51%
- Shares outstanding 264M
- Free float 196M
Inner Mongolia Furui Med Sci company profile
- Company name
- Inner Mongolia Furui Med Sci
- Ticker
- 300049.SHE
- ISIN
- CNE100000KG1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jan 20, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 946
- Fiscal year end
- December
- Address
- Central Tower, Zhonghai Plaza, Beijing, China, 100020
- Phone
- 86 10 8468 2800
- Website
- fu-rui.com
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liver disease; and FibroView data management software. It provides digital health management services; compound turtle shell softening liver tablets; and prescription drugs. The company was formerly known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company. Inner Mongolia Furui Medical Science Co., Ltd. was founded in 1998 and is headquartered in Beijing, China.
Inner Mongolia Furui Med Sci management
5- Mr. Guanyi WangGM & Chairman · born 1970
- Mr. Zhi Guo ShenDeputy GM & CFO · born 1977
- Ms. Lijuan DengDeputy GM & Director · born 1964
- Ms. Xiu Zhen SunBoard Secretary · born 1971
- Ms. Li Qun WangDeputy General Manager · born 1968